Evaluation of Potent and Selective Small-Molecule Antagonists for the CXCR2 Chemokine Receptor

Click to copy article linkArticle link copied!

This article is cited by 65 publications.

1. Bianca Maria Casella, James P. Farmer, Desislava N. Nesheva, Huw E. L. Williams, Steven J. Charlton, Nicholas D. Holliday, Charles A. Laughton, Shailesh N. Mistry. Design, Synthesis, and Application of Fluorescent Ligands Targeting the Intracellular Allosteric Binding Site of the CXC Chemokine Receptor 2. Journal of Medicinal Chemistry 2023, 66 (18) , 12911-12930. https://doi.org/10.1021/acs.jmedchem.3c00849
2. Heng Xu, Hongfu Lu, Zhongmiao Xu, Linbo Luan, Chengyong Li, Yan Xu, Kelly Dong, Jinqiang Zhang, Xiong Li, Yvonne Li, Gentao Liu, Sophie Gong, Yong-Gang Zhao, Ailian Liu, Yueting Zhang, Wei Zhang, Xin Cai, Jia-Ning Xiang, John D. Elliott, and Xichen Lin . Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders. ACS Medicinal Chemistry Letters 2016, 7 (4) , 397-402. https://doi.org/10.1021/acsmedchemlett.5b00489
3. Helen Ha, Bikash Debnath, Srinivas Odde, Tim Bensman, Henry Ho, Paul M. Beringer, and Nouri Neamati . Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models. Journal of Chemical Information and Modeling 2015, 55 (8) , 1720-1738. https://doi.org/10.1021/acs.jcim.5b00181
4. James Pease and Richard Horuk . Chemokine Receptor Antagonists. Journal of Medicinal Chemistry 2012, 55 (22) , 9363-9392. https://doi.org/10.1021/jm300682j
5. Alessio Moriconi, Chiara Bigogno, Gianluca Bianchini, Antonio Caligiuri, Anna Resconi, Massimo G. Dondio, Gaetano D’Anniballe, and Marcello Allegretti . Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors. ACS Medicinal Chemistry Letters 2011, 2 (10) , 768-773. https://doi.org/10.1021/ml2001533
6. Barbara Taferner, Wolfgang Schuehly, Antje Huefner, Igor Baburin, Katharina Wiesner, Gerhard F. Ecker, and Steffen Hering . Modulation of GABAA-Receptors by Honokiol and Derivatives: Subtype Selectivity and Structure–Activity Relationship. Journal of Medicinal Chemistry 2011, 54 (15) , 5349-5361. https://doi.org/10.1021/jm200186n
7. Phuc Ung and David A. Winkler . Tripeptide Motifs in Biology: Targets for Peptidomimetic Design. Journal of Medicinal Chemistry 2011, 54 (5) , 1111-1125. https://doi.org/10.1021/jm1012984
8. Alex Kayongo, Brian Nyiro, Trishul Siddharthan, Bruce Kirenga, William Checkley, Moses Lutaakome Joloba, Jerrold Ellner, Padmini Salgame. Mechanisms of lung damage in tuberculosis: implications for chronic obstructive pulmonary disease. Frontiers in Cellular and Infection Microbiology 2023, 13 https://doi.org/10.3389/fcimb.2023.1146571
9. Margaux Billen, Dominique Schols, Peter Verwilst. Targeting chemokine receptors from the inside-out: discovery and development of small-molecule intracellular antagonists. Chemical Communications 2022, 58 (26) , 4132-4148. https://doi.org/10.1039/D1CC07080K
10. Patrick Hochegger, Johanna Dolensky, Werner Seebacher, Robert Saf, Marcel Kaiser, Pascal Mäser, Robert Weis. 8-Amino-6-Methoxyquinoline—Tetrazole Hybrids: Impact of Linkers on Antiplasmodial Activity. Molecules 2021, 26 (18) , 5530. https://doi.org/10.3390/molecules26185530
11. John G. Montana, Hazel J. Dyke, J. Craig Fox, Nicholas C. Ray. Current and Emerging Therapies in Chronic Obstructive Pulmonary Disease. 2021, 1-47. https://doi.org/10.1002/0471266949.bmc176.pub2
12. Jinxin Che, Rui Song, Binhui Chen, Xiaowu Dong. Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead. European Journal of Medicinal Chemistry 2020, 185 , 111853. https://doi.org/10.1016/j.ejmech.2019.111853
13. Kristen Stout, Marketa Bernaskova, Gary W. Miller, Antje Hufner, Wolfgang Schuehly. Bioinspired Honokiol Analogs and Their Evaluation for Activity on the Norepinephrine Transporter. Molecules 2018, 23 (10) , 2536. https://doi.org/10.3390/molecules23102536
14. Wesam E. Mehanna, Tiangong Lu, Bikash Debnath, Deena S. Lasheen, Rabah A. T. Serya, Khaled A. Abouzid, Nouri Neamati. Synthesis, ADMET Properties, and Biological Evaluation of Benzothiazole Compounds Targeting Chemokine Receptor 2 (CXCR2). ChemMedChem 2017, 12 (13) , 1045-1054. https://doi.org/10.1002/cmdc.201700229
15. Marketa Bernaskova, Angela Schoeffmann, Wolfgang Schuehly, Antje Hufner, Igor Baburin, Steffen Hering. Nitrogenated honokiol derivatives allosterically modulate GABAA receptors and act as strong partial agonists. Bioorganic & Medicinal Chemistry 2015, 23 (20) , 6757-6762. https://doi.org/10.1016/j.bmc.2015.08.034
16. Rupert P. Austin, Colin Bennion, Roger V. Bonnert, Lal Cheema, Anthony R. Cook, Rhona J. Cox, Mark R. Ebden, Alasdair Gaw, Ken Grime, Premji Meghani, David Nicholls, Caroline Phillips, Neal Smith, John Steele, Jeffrey P. Stonehouse. Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists. Bioorganic & Medicinal Chemistry Letters 2015, 25 (7) , 1616-1620. https://doi.org/10.1016/j.bmcl.2015.01.067
17. Hongfu Lu, Ting Yang, Zhongmiao Xu, Paul B. Wren, Yueting Zhang, Xin Cai, Metul Patel, Kelly Dong, Qing Zhang, Wei Zhang, Xiaoming Guan, Jianing Xiang, John D. Elliott, Xichen Lin, Feng Ren. 2-Aminopyrimidin-4(1H)-one as the novel bioisostere of urea: Discovery of novel and potent CXCR2 antagonists. Bioorganic & Medicinal Chemistry Letters 2014, 24 (23) , 5493-5496. https://doi.org/10.1016/j.bmcl.2014.10.003
18. Francoise Bachelerie, Adit Ben-Baruch, Amanda M. Burkhardt, Christophe Combadiere, Joshua M. Farber, Gerard J. Graham, Richard Horuk, Alexander Hovard Sparre-Ulrich, Massimo Locati, Andrew D. Luster, Alberto Mantovani, Kouji Matsushima, Philip M. Murphy, Robert Nibbs, Hisayuki Nomiyama, Christine A. Power, Amanda E. I. Proudfoot, Mette M. Rosenkilde, Antal Rot, Silvano Sozzani, Marcus Thelen, Osamu Yoshie, Albert Zlotnik, . International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors. Pharmacological Reviews 2014, 66 (1) , 1-79. https://doi.org/10.1124/pr.113.007724
19. Marketa Bernaskova, Nadine Kretschmer, Wolfgang Schuehly, Antje Huefner, Robert Weis, Rudolf Bauer. Synthesis of Tetrahydrohonokiol Derivates and Their Evaluation for Cytotoxic Activity against CCRF-CEM Leukemia, U251 Glioblastoma and HCT-116 Colon Cancer Cells. Molecules 2014, 19 (1) , 1223-1237. https://doi.org/10.3390/molecules19011223
20. Dominique Gales, Clarence Clark, Upender Manne, Temesgen Samuel. The Chemokine CXCL8 in Carcinogenesis and Drug Response. ISRN Oncology 2013, 2013 , 1-8. https://doi.org/10.1155/2013/859154
21. Brian R Leaker, Peter J Barnes, Brian O’Connor. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. Respiratory Research 2013, 14 (1) , 137. https://doi.org/10.1186/1465-9921-14-137
22. Federico Carbone, Alessio Nencioni, François Mach, Nicolas Vuilleumier, Fabrizio Montecucco. Pathophysiological role of neutrophils in acute myocardial infarction. Thrombosis and Haemostasis 2013, 110 (09) , 501-514. https://doi.org/10.1160/TH13-03-0211
23. Séverine Denoyelle, Ting Chen, Limo Chen, Yibo Wang, Edvin Klosi, José A. Halperin, Bertal H. Aktas, Michael Chorev. In vitro inhibition of translation initiation by N,N′-diarylureas—potential anti-cancer agents. Bioorganic & Medicinal Chemistry Letters 2012, 22 (1) , 402-409. https://doi.org/10.1016/j.bmcl.2011.10.126
24. Petra de Kruijf, Herman D. Lim, Luc Roumen, Véronique A. Renjaän, Jiuqiao Zhao, Maria L. Webb, Douglas S. Auld, Jac. C.H.M. Wijkmans, Guido J. R. Zaman, Martine J. Smit, Chris de Graaf, Rob Leurs. Identification of a Novel Allosteric Binding Site in the CXCR2 Chemokine Receptor. Molecular Pharmacology 2011, 80 (6) , 1108-1118. https://doi.org/10.1124/mol.111.073825
25. Robert J. Snelgrove. Targeting of a common receptor shared by CXCL8 and N-Ac-PGP as a therapeutic strategy to alleviate chronic neutrophilic lung diseases. European Journal of Pharmacology 2011, 667 (1-3) , 1-5. https://doi.org/10.1016/j.ejphar.2011.05.073
26. Hongwei Yao, Irfan Rahman. Environment and the Role of Inflammation in Chronic Pulmonary Diseases. 2011https://doi.org/10.1201/b11014-4
27. Hongwei Yao, Irfan Rahman. Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicology and Applied Pharmacology 2011, 254 (2) , 72-85. https://doi.org/10.1016/j.taap.2009.10.022
28. Katsuhiro Mihara, Jac Wijkmans. Low Molecular Weight CXCR2 Antagonists as Promising Therapeutics. 2010, 279-299. https://doi.org/10.1002/9783527631995.ch12
29. John G. Montana, Hazel J. Dyke, J. Craig Fox, Nicholas C. Ray. Current and Emerging Therapies in Chronic Obstructive Pulmonary Disease. 2010, 747-790. https://doi.org/10.1002/0471266949.bmc176
30. Pancham Bakshi, Chao Jin, Pierre Broutin, Beniam Berhane, Jon Reed, Michael Mullan. Structural optimization of a CXCR2-directed antagonist that indirectly inhibits γ-secretase and reduces Aβ. Bioorganic & Medicinal Chemistry 2009, 17 (23) , 8102-8112. https://doi.org/10.1016/j.bmc.2009.09.051
31. Shilan Liu, Yinhui Liu, Hongmei Wang, YiLi Ding, Hao Wu, Jingchao Dong, Angela Wong, Shu-Hui Chen, Ge Li, Manuel Chan, Nicole Sawyer, Francois G. Gervais, Martin Henault, Stacia Kargman, Leanne L. Bedard, Yongxin Han, Rick Friesen, Robert B. Lobell, David M. Stout. Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2009, 19 (19) , 5741-5745. https://doi.org/10.1016/j.bmcl.2009.08.014
32. ME Bradley, ME Bond, J Manini, Z Brown, SJ Charlton. SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. British Journal of Pharmacology 2009, 158 (1) , 328-338. https://doi.org/10.1111/j.1476-5381.2009.00182.x
33. Petra de Kruijf, Jane van Heteren, Herman D. Lim, Paolo G.M. Conti, Miranda M. C. van der Lee, Leontien Bosch, Koc-Kan Ho, Douglas Auld, Michael Ohlmeyer, Martin J. Smit, Jac C. H. M. Wijkmans, Guido J.R. Zaman, Martine J. Smit, Rob Leurs. Nonpeptidergic Allosteric Antagonists Differentially Bind to the CXCR2 Chemokine Receptor. Journal of Pharmacology and Experimental Therapeutics 2009, 329 (2) , 783-790. https://doi.org/10.1124/jpet.108.148387
34. David J. Nicholls, Nick P. Tomkinson, Katherine E. Wiley, Anne Brammall, Lorna Bowers, Caroline Grahames, Alasdair Gaw, Premji Meghani, Philip Shelton, Tracey J. Wright, Philip R. Mallinder. Identification of a Putative Intracellular Allosteric Antagonist Binding-Site in the CXC Chemokine Receptors 1 and 2. Molecular Pharmacology 2008, 74 (5) , 1193-1202. https://doi.org/10.1124/mol.107.044610
35. Younong Yu, Michael P. Dwyer, Jianping Chao, Cynthia Aki, Jianhua Chao, Biju Purakkattle, Diane Rindgen, Richard Bond, Rosemary Mayer-Ezel, James Jakway, Hongchen Qiu, R. William Hipkin, James Fossetta, Waldemar Gonsiorek, Hong Bian, Xuedong Fan, Carol Terminelli, Jay Fine, Daniel Lundell, J. Robert Merritt, Zhenmin He, Gaifa Lai, Minglang Wu, Arthur Taveras. Synthesis and structure–activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2008, 18 (4) , 1318-1322. https://doi.org/10.1016/j.bmcl.2008.01.024
36. C A Lunn, E‐P Reich, J S Fine, B Lavey, J A Kozlowski, R W Hipkin, D J Lundell, L Bober. Biology and therapeutic potential of cannabinoid CB 2 receptor inverse agonists. British Journal of Pharmacology 2008, 153 (2) , 226-239. https://doi.org/10.1038/sj.bjp.0707480
37. Alessio Moriconi, Maria Candida Cesta, Maria Neve Cervellera, Andrea Aramini, Silvia Coniglio, Sandro Colagioia, Andrea Rosario Beccari, Cinzia Bizzarri, Michela Rita Cavicchia, Massimo Locati, Emanuela Galliera, Paola Di Benedetto, Paolo Vigilante, Riccardo Bertini, Marcello Allegretti. Design of Noncompetitive Interleukin-8 Inhibitors Acting on CXCR1 and CXCR2. Journal of Medicinal Chemistry 2007, 50 (17) , 3984-4002. https://doi.org/10.1021/jm061469t
38. Jianhua Chao, Arthur G. Taveras, Jianping Chao, Cynthia Aki, Michael Dwyer, Younong Yu, Biju Purakkattle, Diane Rindgen, James Jakway, William Hipkin, James Fosetta, Xuedong Fan, Daniel Lundell, Jay Fine, Michael Minnicozzi, Jonathan Phillips, J. Robert Merritt. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2007, 17 (13) , 3778-3783. https://doi.org/10.1016/j.bmcl.2007.04.016
39. Yonghui Wang, Jakob Busch-Petersen, Feng Wang, Lanping Ma, Wei Fu, Jeffrey K. Kerns, Jian Jin, Michael R. Palovich, Jing-Kang Shen, Miriam Burman, James J. Foley, Dulcie B. Schmidt, Gerald E. Hunsberger, Henry M. Sarau, Katherine L. Widdowson. 3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists. Bioorganic & Medicinal Chemistry Letters 2007, 17 (14) , 3864-3867. https://doi.org/10.1016/j.bmcl.2007.05.011
40. Purakkattle Biju, Younong Yu. A new synthesis of 3,4-disubstituted 1,2,5-thiadiazoles. Tetrahedron Letters 2007, 48 (30) , 5279-5282. https://doi.org/10.1016/j.tetlet.2007.05.123
41. B. R. Celli, P. J. Barnes. Exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal 2007, 29 (6) , 1224-1238. https://doi.org/10.1183/09031936.00109906
42. Igor A. Schepetkin, Liliya N. Kirpotina, Andrei I. Khlebnikov, Mark T. Quinn. High-Throughput Screening for Small-Molecule Activators of Neutrophils: Identification of Novel N -Formyl Peptide Receptor Agonists. Molecular Pharmacology 2007, 71 (4) , 1061-1074. https://doi.org/10.1124/mol.106.033100
43. Brent W. McCleland, Roderick S. Davis, Michael R. Palovich, Katherine L. Widdowson, Michelle L. Werner, Miriam Burman, James J. Foley, Dulcie B. Schmidt, Henry M. Sarau, Martin Rogers, Kevin L. Salyers, Peter D. Gorycki, Theresa J. Roethke, Gary J. Stelman, Leonard M. Azzarano, Keith W. Ward, Jakob Busch-Petersen. Comparison of N,N′-diarylsquaramides and N,N′-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorganic & Medicinal Chemistry Letters 2007, 17 (6) , 1713-1717. https://doi.org/10.1016/j.bmcl.2006.12.067
44. Grant C. Nicholson, Rachel C. Tennant, Donald C. Carpenter, Henry M. Sarau, Onn Min Kon, Peter J. Barnes, Michael Salmon, Rupert S. Vessey, Ruth Tal-Singer, Trevor T. Hansel. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: Upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. Pulmonary Pharmacology & Therapeutics 2007, 20 (1) , 52-59. https://doi.org/10.1016/j.pupt.2005.11.009
45. Dennis M. Lindell, Nicholas W. Lukacs. Chemokine Receptors in Allergic Lung Disease. 2007, 235-257. https://doi.org/10.1007/978-1-59745-020-1_12
46. Michael P. Dwyer, Younong Yu, Jianping Chao, Cynthia Aki, Jianhua Chao, Purakkattle Biju, Viyyoor Girijavallabhan, Diane Rindgen, Richard Bond, Rosemary Mayer-Ezel, James Jakway, R. William Hipkin, James Fossetta, Waldemar Gonsiorek, Hong Bian, Xuedong Fan, Carol Terminelli, Jay Fine, Daniel Lundell, J. Robert Merritt, Laura L. Rokosz, Bernd Kaiser, Ge Li, Wei Wang, Tara Stauffer, Lynne Ozgur, John Baldwin, Arthur G. Taveras. Discovery of 2-Hydroxy- N , N -dimethyl-3-{2-[[( R )-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123):  A Potent, Orally Bioavailable CXCR2/CXCR1 Receptor Antagonist. Journal of Medicinal Chemistry 2006, 49 (26) , 7603-7606. https://doi.org/10.1021/jm0609622
47. Hong Nie, Katherine L. Widdowson, Michael R. Palovich, Wei Fu, John D. Elliott, Deborah L. Bryan, Miriam Burman, Dulcie B. Schmidt, James J. Foley, Henry M. Sarau, Jakob Busch-Petersen. N,N′-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors. Bioorganic & Medicinal Chemistry Letters 2006, 16 (21) , 5513-5516. https://doi.org/10.1016/j.bmcl.2006.08.042
48. Cinzia Bizzarri, Andrea Rosario Beccari, Riccardo Bertini, Michela Rita Cavicchia, Simona Giorgini, Marcello Allegretti. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacology & Therapeutics 2006, 112 (1) , 139-149. https://doi.org/10.1016/j.pharmthera.2006.04.002
49. Louise E. Donnelly, Peter J. Barnes. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends in Pharmacological Sciences 2006, 27 (10) , 546-553. https://doi.org/10.1016/j.tips.2006.08.001
50. J. Robert Merritt, Laura L. Rokosz, Kingsley H. Nelson, Bernd Kaiser, Wei Wang, Tara M. Stauffer, Lynne E. Ozgur, Adriane Schilling, Ge Li, John J. Baldwin, Arthur G. Taveras, Michael P. Dwyer, Jianping Chao. Synthesis and structure–activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists. Bioorganic & Medicinal Chemistry Letters 2006, 16 (15) , 4107-4110. https://doi.org/10.1016/j.bmcl.2006.04.082
51. Samir Malhotra, S F Paul Man, Don D Sin. Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Emerging Drugs 2006, 11 (2) , 275-291. https://doi.org/10.1517/14728214.11.2.275
52. J. C. Virchow. COPD — zukünftige Therapieoptionen. Der Pneumologe 2006, 3 (2) , 129-139. https://doi.org/10.1007/s10405-006-0086-z
53. Toshiyuki Yamagata, Masakazu Ichinose. Agents against cytokine synthesis or receptors. European Journal of Pharmacology 2006, 533 (1-3) , 289-301. https://doi.org/10.1016/j.ejphar.2005.12.046
54. Charles A. Lunn, Jay S. Fine, Alberto Rojas-Triana, James V. Jackson, Xuedong Fan, Ted T. Kung, Waldemar Gonsiorek, Martin A. Schwarz, Brian Lavey, Joseph A. Kozlowski, Satwant K. Narula, Daniel J. Lundell, R. William Hipkin, Loretta A. Bober. A Novel Cannabinoid Peripheral Cannabinoid Receptor-Selective Inverse Agonist Blocks Leukocyte Recruitment in Vivo. Journal of Pharmacology and Experimental Therapeutics 2006, 316 (2) , 780-788. https://doi.org/10.1124/jpet.105.093500
55. Andrei I. Khlebnikov, Igor A. Schepetkin, Mark T. Quinn. Quantitative structure–activity relationships for small non-peptide antagonists of CXCR2: Indirect 3D approach using the frontal polygon method. Bioorganic & Medicinal Chemistry 2006, 14 (2) , 352-365. https://doi.org/10.1016/j.bmc.2005.08.026
56. Christopher A. Haskell, Richard Horuk, Meina Liang, Mary Rosser, Laura Dunning, Imadul Islam, Leonor Kremer, Julio Gutiérrez, Gabriel Marquez, Carlos Martinez-A, Mark J. Biscone, Robert W. Doms, Sofia Ribeiro. Identification and Characterization of a Potent, Selective Nonpeptide Agonist of the CC Chemokine Receptor CCR8. Molecular Pharmacology 2006, 69 (1) , 309-316. https://doi.org/10.1124/mol.105.014779
57. Marcello Allegretti, Riccardo Bertini, Maria Candida Cesta, Cinzia Bizzarri, Rosa Di Bitondo, Vito Di Cioccio, Emanuela Galliera, Valerio Berdini, Alessandra Topai, Giuseppe Zampella, Vincenzo Russo, Nicoletta Di Bello, Giuseppe Nano, Luca Nicolini, Massimo Locati, Piercarlo Fantucci, Saverio Florio, Francesco Colotta. 2-Arylpropionic CXC Chemokine Receptor 1 (CXCR1) Ligands as Novel Noncompetitive CXCL8 Inhibitors. Journal of Medicinal Chemistry 2005, 48 (13) , 4312-4331. https://doi.org/10.1021/jm049082i
58. P. J. Barnes, R. A. Stockley. COPD: current therapeutic interventions and future approaches. European Respiratory Journal 2005, 25 (6) , 1084-1106. https://doi.org/10.1183/09031936.05.00139104
59. M. D. Morgan, L. Harper, X. Lu, G. Nash, J. Williams, C. O. S. Savage. Can neutrophils be manipulated in vivo?. Rheumatology 2005, 44 (5) , 597-601. https://doi.org/10.1093/rheumatology/keh507
60. Alison E. John, Keith M. Channon, David R. Greaves. Chemokines, Chemokine Receptors and Atherosclerosis. 2005, 223-253. https://doi.org/10.1016/S1063-5823(04)55009-3
61. Linda Bendall, Kenneth Bradstock. New Therapies Targeting Chemokine Receptors: Can Changing the Way Cells Traffic be Used to Treat Human Disease?. 2005, 331-365. https://doi.org/10.1016/S1063-5823(04)55012-3
62. . Novel pyrimidine-based CXCR2 chemokine receptor antagonists. Expert Opinion on Therapeutic Patents 2004, 1507-1510. https://doi.org/10.1517/13543776.14.10.1507
63. Qi Jin, Hong Nie, Brent W. McCleland, Katherine L. Widdowson, Michael R. Palovich, John D. Elliott, Richard M. Goodman, Miriam Burman, Henry M. Sarau, Keith W. Ward, Melanie Nord, Bonnie M. Orr, Peter D. Gorycki, Jakob Busch-Petersen. Discovery of potent and orally bioavailable N,N′-diarylurea antagonists for the CXCR2 chemokine receptor. Bioorganic & Medicinal Chemistry Letters 2004, 14 (17) , 4375-4378. https://doi.org/10.1016/j.bmcl.2004.06.097
64. Michele A Weidner-Wells, Todd C Henninger, Stephanie A Fraga-Spano, Christine M Boggs, Michele Matheis, David M Ritchie, Dennis C Argentieri, Michael P Wachter, Dennis J Hlasta. Synthesis and structure–activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleukin-8 (IL-8) receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2004, 14 (16) , 4307-4311. https://doi.org/10.1016/j.bmcl.2004.05.080
65. John R. White, Henry M. Sarau. IL-8 receptor antagonist: basic research and clinical utility. , 89-102. https://doi.org/10.1007/978-3-7643-7437-2_7